Akero says MASH drug reverses liver damage in study, doubling shares

Akero Smashes Expectations in MASH, Showing Its Drug Reverses Fibrosis in Fatty Livers

Akero Therapeutics reported that at 96 weeks, 39% of patients who received the 50 mg dose of efruxifermin achieved improvement in fibrosis, or liver scarring, caused by the fatty liver disease MASH. This study previously failed to achieve statistically significant improvement at 36 weeks, but Akero executives say the latest results show that longer dosing matters. The post Akero Smashes Expectations in MASH, Showing Its Drug Reverses Fibrosis in…

Akero says MASH drug reverses liver damage in study, doubling shares

Results showing Akero’s efruxifermin improved fibrosis by more than what Wall Street expected lifted the stock of both it and rival MASH developer 89bio.

Akero drug reverses liver scarring in study of severe MASH patients

The performance of Akero's drug, called efruxifermin, in the severe MASH study outperformed investors' expectations.

Akero: Reversal Of Cirrhosis With EFX Is A "First" In F4 MASH Patients (NASDAQ:AKRO)

This article was written by Follow Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare. He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis…

A monster, MASH - Sanford Burnham Prebys

Scientists show how the advanced form of fatty liver disease has monstrous effects on liver cancer risk Liver cancer has proven to be a tough beast to tame. Experts expected rates of the cancer to decrease following the development of the hepatitis B vaccine in the 1980s, which reduced one of the major risk factors for the disease. Research in Taiwan showed that its universal infant hepatitis B vaccination program led to young adults experienci…

Akero's cirrhosis treatment shows promise in Phase IIb study

Akero Therapeutics has revealed preliminary outcomes from its Phase IIb study of EFX in individuals with compensated cirrhosis (F4)The post Akero’s cirrhosis treatment shows promise in Phase IIb study appeared first on Clinical Trials Arena.